Phone: +45 27 51 26 22
Diabetic nephropathyNew risk markers for early signs of development of diabetic nephropathy. Short-term trials of different treatment modalities to prevent or delay progression of diabetic kidney disease.
Pharmacoepidemiology How is treatment recommendations implemented, nationally and globally? Are there differences between the Nordic countries? Do differences in treatment patterns lead to different outcome?
Aim: Effect of dapagliflozin treatment on urinary peptide patterns.
Collaborators: AstraZeneca, Jens Faber (Denmark), Niklas R Jørgensen (Denmark), Erling B Petersen (Denmark), Harald Michak (Germany).
Aim: Allopurinol treatment to prevent diabetic nephropathy in type 1 diabetes.
Collaborators: Joslin Diabetes Center (USA), NIDDK (USA), JDRF (USA) and a number of North American universities and hospitals.
CVD REAL Nordic
Aim: Effect of SGLT2 inhibitors on real-life outcome in the Nordic nationwide healthcare registries.
Collaborators: AstraZeneca and Swedish, Norwegian, Finnish Universities.
Aim: Individualized prevention and treatment of diabetic nephropathy.
Collaborators: NovoNordisk Foundation, Joslin Diabetes Center (USA), University Medical Center Groningen (The Netherlands), Folkhälsan Helsinki (Finland).
Aim: Individualized prevention and treatment of diabetic nephropathy using urinary peptide patterns.
Collaborators: EU and a number of European universities.
Aim: Dapagliflozin for patients with type 2 diabetes and nephropathy.